Ayala Pharmaceuticals, Inc.
Industry
- Biotechnology
- Drug Discovery Technologies
- Bioinformatics
- Drug Discovery Technologies
- Pharmaceuticals
- Vaccines
Other Names/Subsidiaries
- Biosight
Latest on Ayala Pharmaceuticals, Inc.
OS Therapies Incorporated launched the 14th biopharmaceutical company initial public offering in the US in 2024 on 31 July, selling 1.6 million shares at $4 each to gross $6.4m in the smallest IPO so
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Bristol, VantAI Pair Technologies In Pr
Biomedtracker’s latest report on biopharmaceutical company fundraising shows a 25.1% decline in year-over-year dollars raised, from $17.5bn in the fourth quarter of 2022 to $13.1bn in Q4 of 2023. Foll
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novartis And Ionis Build On Earlier Akc